FilingReader Intelligence
Innovent Biologics reports 35% revenue growth in H1
August 7, 2025 at 09:39 AM UTC•By FilingReader AI
Innovent Biologics achieved total product revenue exceeding RMB5.2 billion in H1 2025, representing over 35% year-on-year growth.
The company now has 16 approved products, including mazdutide for weight management approved by China's NMPA. Growth was driven by strong oncology performance and new products.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
HKEX:1801•Hong Kong Exchange
News Alerts
Get instant email alerts when Innovent Biologics Inc publishes news
Free account required • Unsubscribe anytime